DOCSLIB.ORG

Modern Pathology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Modern Pathology VOLUME 32 | SUPPLEMENT 2 | MARCH 2019 MODERN PATHOLOGY 2019 ABSTRACTS NEUROPATHOLOGY AND OPHTHALMIC PATHOLOGY (1621-1666) MARCH 16-21, 2019 PLATF OR M & 2 01 9 ABSTRACTS P OSTER PRESENTATI ONS EDUCATI ON C O M MITTEE Jason L. Hornick , C h air Ja mes R. Cook R h o n d a K. Y a nti s s, Chair, Abstract Revie w Board S ar a h M. Dr y and Assign ment Co m mittee Willi a m C. F a q ui n Laura W. La mps , Chair, C ME Subco m mittee C ar ol F. F ar v er St e v e n D. Billi n g s , Interactive Microscopy Subco m mittee Y uri F e d ori w Shree G. Shar ma , Infor matics Subco m mittee Meera R. Ha meed R aj a R. S e et h al a , Short Course Coordinator Mi c h ell e S. Hir s c h Il a n W ei nr e b , Subco m mittee for Unique Live Course Offerings Laksh mi Priya Kunju D a vi d B. K a mi n s k y ( Ex- Of ici o) A n n a M ari e M ulli g a n Aleodor ( Doru) Andea Ri s h P ai Zubair Baloch Vi nita Parkas h Olca Bast urk A nil P ar w a ni Gregory R. Bean , Pat h ol o gist-i n- Trai ni n g D e e p a P atil D a ni el J. Br at K wun Wah Wen , Pat h ol o gist-i n- Trai ni n g Ashley M. Ci mino- Mathe ws ABSTRACT REVIE W B OARD Benja min Ada m Ta mara Giorgadze Ta mara Lotan Steven Salvatore Mi c h ell e Af k h a mi Raul Gonzalez Anthony Magliocco Souzan Sanati Narasi mhan ( Narsi) Agara m Purva Gopal Kr uti M a ni ar Sandro Santagata R o u b a Ali- F e h mi Anuradha Gopalan Jonathan Marotti A nj ali S a qi G h a s s a n All o Jennifer Gordetsky E mil y M a s o n Frank Schneider Isabel Alvarado- Cabrero Rondell Graha m Jerri McLe more Jeanne Shen C hristi na Ar n ol d Alejandro Gru Bruce Mc Manus Ji a qi S hi Rohit Bhargava Nil e s h G u pt a David Meredith Wun-Ju Shieh Justin Bishop Ma mta Gupta A n n e Mill s G a bri el Si c a Jennifer Boland Kriszti na Ha nley Neda Moata med D e e pi k a Sir o hi Ele na Brac htel Douglas Hart man Sara Monaco K alli o pi Si zi o pi k o u M aril y n B ui Yael He her Atis Muehlenbachs Lauren S mith S helley Calt har p Walter He nricks Bit a N ai ni Sara Szabo Joanna Chan J o h n Hi g gi n s Di a n n a N g J ulie Ter uya-Fel dstei n Jennifer Chap man M ai H o a n g Tony Ng Gaetano Thiene H ui C h e n M oj g a n H o s s ei ni Ericka Ol gaar d Khin Th way Yi n g b ei C h e n Aaron Huber Jac q ueli ne Parai Rash mi Tondon Benja min Chen P et er Ill ei Yan Peng Jose Torrealba Rebecca Chernock D oi n a I v a n D a vi d Pi s a pi a E vi V a ki a ni Bet h Clark W ei Ji a n g Alexandros Polydorides Christopher VandenBussche Ja mes Conner Vi c ki e J o Sona m Prakash Sonal Var ma Alejandro Contreras Kirk J o nes Manju Prasad E n di W a n g Cla u di u C otta Neerja Ka mbha m Peter Pytel Christopher Weber Ti mothy D’ Alfonso Chiah Sui ( Sunny) Kao Joseph Rabban Olga Weinberg Farbod Darvishian Dipti Kara mchandani Stanley Radio Sara Wobker Jessica Davis Darcy Kerr E mad Rakha Mi n a X u Heather Da wson Ashraf Khan Preetha Ra malinga m Shaofeng Yan Elizabeth De micco Rebecca King Pri y a R a o A nj a n a Y el d a n di Suzanne Dintzis Mi c h a el Kl u k Robyn Reed A ki hi k o Y o s hi d a Mi c h ell e D o w n e s Kristine Konopka Mi c h ell e R ei d Gl ori a Y o u n g D a ni el D y e Gre g or Kri n gs Natasha Rekht man Minghao Zhong Andre w Evans Asangi Ku marapeli Mi c h a el Ri v er a Y a oli n Z h o u Mi c h a el F e el y Alvaro Laga Mi c h a el R o h Hongfa Zhu De n nis Firc ha u Cheng- Han Lee Andres Ro ma Debra Zynger Larissa F urta d o Z ai b o Li Avi Rosenberg A nt h o n y Gill H ai y a n Li u Est her ( Dia na) R ossi R y a n Gill Xi uli Li u Peter Sado w P a ul a Gi nt er Yen- Chun Liu S a i a S al ari a T o cit e a b str a ct s i n t hi s p u bli c ati o n, pl e a s e u s e t h e f oll o wi n g f or m at: A ut h or A, A ut h or B, A ut h or C, et al. A b str a ct titl e ( a b s #). I n “ Fil e Titl e. ” Modern Pathology 2019; 32 (s u p pl 2): pa ge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`aE";%C9-'C3I"J$-"+%9'"$93C25209@"062GC$";%CC-6'"G%3"@69K69F26+"D'bNE"G$95-"32594";%CC-6'"G%3"2K3-6L-4"9'"2'-"@%3-I" =-69'-*6%5"9'L%392'"G%3"F2*'4"9'"\"D\\_E"@%3-3I"?-@*66-'@-"2@@*66-4"9'"\\_"@%3-3"D\`aE,"5:+;$"'24-"H"3:3C-+9@"+-C%3C%393"9'".`a"@%3-3" D.._E"H"CG2";%C9-'C3"G9C$"+-C%3C%393"49-4I""(4L%'@-"J"3C%0-"DcJ.E"G%3"F2*'4"9'"^Q_"@%3-3"D^`aEI"1:C2;5%3+9@"2L-6-M;6-3392'"2F"<2C@$!" G%3"4-C-@C-4"9'"SS_"DS`aE"@%3-3I"<2"3C%C93C9@%55:"390'9F9@%'C"@266-5%C92'"G%3"F2*'4"K-CG--'";62C-9'"-M;6-3392'"2F"<2C@$!" H@59'9@2;%C$25209@%5"$90$"6938"F-%C*6-3I"W-'-"-M;6-3392'"%'%5:393"2F"%55"a"@%3-3"3$2G-4"*;6-0*5%C92'"9'"QS_"@%3-3"DQ`aEI"/%;5%'">-9-6" 3*6L9L%5"%'%5:393"3$2G-4"390'9F9@%'C"%332@9%C92'"2F";226"493-%3-"F6--"3*6L9L%5"G9C$";-69'-*6%5"9'L%392'"D;"b"PIPdNE"H"%4L%'@-"J"3C%0-"D;b" PIPdNEI" <,-16?*+,-*@"[L-6-M;6-3392'"2F"<2C@$!";62C-9'"H"0-'-"G%3"2K3-6L-4"9'"SS_"H"QS_"(11"@%3-3"6-3;-@C9L-5:"9'"C$93"3C*4:I"(";226"493-%3-" F6--"3*6L9L%5"G%3"F2*'4"C2"K-"390'9F9@%'C5:"%332@9%C-4"G9C$";-69'-*6%5"9'L%392'"D;bPIPdNE"H"%4L%'@-"J"3C%0-"D;bPIPdNEI"("5%60-6";%C9-'C" @2$26C"G2*54"09L-"K-CC-6"9'390$C"9'C2"625-"2F"<2C@$"!"%3"%";620'23C9@"H"C$-6%;-*C9@"C%60-CI" !"##$$$<25(510)(+D50+,-$,.$E-.+60(50+-4$96+,85*$F=$02)$G-1,*15-$</H$I6?*$;**5=$5-:$<,8'5(+*,-$0,$/)&0J 9)-)(50+,-$3)K?)-1+-4$L/93M$5-:$N6?,()*1)-0$+-$3+0?$O=F(+:+D50+,-$LNE3OM$:505$$ 1$693C9'%"(;;9'!,"e9'G-'">%2.,"V95--'"79092\,"U%'9-5"76%C\,"16%90"R26K9'389d,"f9':%'"g*d"" !4.9+75-*+-9&$:&(;-9*(+<3$=7(1)>.3$%?3$84.9+75-*+-9&$0-'(1(&-3$=7(1)>.3$%[email protected]+75-*+-9&$:&(;-9*(+<$A-(&B-9>$217..#$./$ 0-'(1(&-3$=7(1)>.3$%?3$C=7(1)>.3$%?"" >+*16,*?()*@"1$693C9'%"(;;9'A"<2'-B"e9'G-'">%2A"<2'-B"V95--'"79092A"<2'-B"U%'9-5"76%CA"<2'-B"16%90"R26K9'389A"<2'-B"f9':%'"g*A"<2'-" A51B4(,?-:@"T'F95C6%C9'0"0592+%3"9'@5*4-"%3C62@:C2+%3"DhR["06%4-3"TTZTiE"%'4"259024-'4620592+%3"DhR["06%4-3"TTZTTTEI"J$-3-"C*+263"%6-" 9'@*6%K5-"K:"3*609@%5"6-3-@C92'"%'4"-L-'C*%55:";6206-33"C2"$90$-6"06%4-"C*+263I"T'"6-@-'C":-%63,"+25-@*5%6"%'4"@:C20-'-C9@";62F959'0" 9'@5*49'0"F5*26-3@-'C"9'"39C*"$:K6949&%C92'"DjT#RE,"'-MCZ0-'-6%C92'"3-X*-'@9'0"D<W#E,"%'4"#<="+9@62%66%:3"$%L-"-'%K5-4"C$-"0-'2+9@" @$%6%@C-69&%C92'"2F"C$-3-"C*+263"F26"F*6C$-6"@5%339F9@%C92'I" >)*+4-@"h-"9'C-06%C-4"jT#R,"<W#"%'4"C$-"#<="['@23@%'"%33%:"C2"%33-33"C$-"0-'2+9@"%K-66%C92'3"9'"K6%9'"C*+263"F26"+25-@*5%6" @5%339F9@%C92'I"h-"@266-5%C-4"C$-"['@23@%'"4%C%"G9C$"C$-"<W#"%'4"jT#R"4%C%I" C)*?60*@"h-"9'@5*4-4"\N"9'F95C6%C9'0"0592+%3"9'"C$-"3C*4:I"J$-6-"G-6-".P"0592K5%3C2+%3"DW7>3E,"N"%'%;5%3C9@"%3C62@:C2+%3,"!"49FF*3-" %3C62@:C2+%,"%'4"a"259024-'4620592+%3,"N"2F"G$9@$"G-6-"%'%;5%3C9@"@%3-3I"(55"\N"@%3-3"G-6-"%33-33-4"F26"@2;:"'*+K-6"%K-66%C92'3" D1<(3E"*39'0"['@2#@%'I"<W#"%'4"jT#R"F26"!;`!aX"@2Z4-5-C92'"G-6-";-6F26+-4"2'"\."%'4"!P"2F"C$-"C*+263,"6-3;-@C9L-5:I"[F"C$-"9'F95C6%C9'0" %3C62@:C2+%3,".P"G-6-"TURZG954C:;-"%'4"^"G-6-"TURZ+*C%'CI"J$-"['@23@%'"1<i"=5*3"(33%:"4-C-@C-4"S\"2F"C$-"S^"@2;:"'*+K-6"L%69%C92'3" C$%C"G-6-"4-C-@C-4"K:"<W#,"3$2G9'0"%"a^IN_"@266-5%C92'I"(55"@%3-3"2F"!;`!aX"@2Z4-5-C92'"4-C-@C-4"K:"jT#R"DS"@%3-3E"G-6-"4-C-@C-4"K:"C$-" ['@23@%'"%33%:"%'4"C$-"CG2"@%3-3"C$%C"G-6-"'-0%C9L-"K:"jT#R"D."@%3-3E"G-6-"%532"'-0%C9L-"K:"['@23@%',"3$2G9'0"!PP_"@2'@264%'@-I" TURZG954C:;-"W7>3"%'4"%'%;5%3C9@"%3C62@:C2+%3"3$2G-4"C$-"+23C"@2+;5-M"@:C20-'-C9@";62F95-3,"G9C$"C$-"+23C"F6-X*-'C"%5C-6%C92'3"K-9'0" ;%6C9%5"4-5-C92'3,"3--'"9'"!PP_"2F"C$-"C*+263,"F2552G-4"K:"G$25-"@$62+232+-"4-5-C92'3"DSN_E,";%6C9%5"0%9'3"DSP_E,"G$25-"@$62+232+-" 0%9'3"DQP_E,"%'4"%+;59F9@%C92'"-L-'C3"D^N_EI"12;:"'-*C6%5"5233"2F"$-C-62&:0239C:"Dg[RE"G%3"5-33"@2++2'"D\P_EI"(55"TURZ+*C%'C" %3C62@:C2+%3"3$2G-4"5-33"F6-X*-'C";%6C9%5"4-5-C92'3,"@2;:"'-*C6%5"g[R,"%'4";%6C9%5"0%9'3"$2G-L-6,"G$25-"@$62+232+-"4-5-C92'3"G-6-" 3--'"9'"^Q_I"[59024-'4620592+%3"G-6-"@$%6%@C-69&-4"K:"G$25-"@$62+232+-"%6+"5233-3"2F"!;"%'4"!aX,"G9C$"L-6:"F-G"9325%C-4";%6C9%5"0%9'3" ! !" ! %'4"4-5-C92'3"%'4"'2"%+;59F9@%C92'"-L-'C3I"('%;5%3C9@"259024-'4620592+%3"3$2G-4"G$25-"@$62+232+-"4-5-C92'3"%'4"@2;:"'-*C6%5"g[R" -L-'C3"C$%C"G-6-"'2C"3--'"9'"06%4-"."C*+263I"
Load more

Recommended publications
  • Neurofibromatosis Type 2 (NF2)
    International Journal of Molecular Sciences Review Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis Suha Bachir 1,† , Sanjit Shah 2,† , Scott Shapiro 3,†, Abigail Koehler 4, Abdelkader Mahammedi 5 , Ravi N. Samy 3, Mario Zuccarello 2, Elizabeth Schorry 1 and Soma Sengupta 4,* 1 Department of Genetics, Cincinnati Children’s Hospital, Cincinnati, OH 45229, USA; [email protected] (S.B.); [email protected] (E.S.) 2 Department of Neurosurgery, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] (S.S.); [email protected] (M.Z.) 3 Department of Otolaryngology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] (S.S.); [email protected] (R.N.S.) 4 Department of Neurology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] 5 Department of Radiology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] * Correspondence: [email protected] † These authors contributed equally. Abstract: Patients diagnosed with neurofibromatosis type 2 (NF2) are extremely likely to develop meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary brain tumor; many NF2 patients suffer from multiple meningiomas. In NF2, patients have mutations in the NF2 gene, specifically with loss of function in a tumor-suppressor protein that has a number of synonymous names, including: Merlin, Neurofibromin 2, and schwannomin. Merlin is a 70 kDa protein that has 10 different isoforms. The Hippo Tumor Suppressor pathway is regulated upstream by Merlin. This pathway is critical in regulating cell proliferation and apoptosis, characteristics that are important for tumor progression.
    [Show full text]
  • Central Nervous System Cancers Panel Members Can Be Found on Page 1151
    1114 NCCN David Tran, MD, PhD; Nam Tran, MD, PhD; Frank D. Vrionis, MD, MPH, PhD; Patrick Y. Wen, MD; Central Nervous Nicole McMillian, MS; and Maria Ho, PhD System Cancers Overview In 2013, an estimated 23,130 people in the United Clinical Practice Guidelines in Oncology States will be diagnosed with primary malignant brain Louis Burt Nabors, MD; Mario Ammirati, MD, MBA; and other central nervous system (CNS) neoplasms.1 Philip J. Bierman, MD; Henry Brem, MD; Nicholas Butowski, MD; These tumors will be responsible for approximately Marc C. Chamberlain, MD; Lisa M. DeAngelis, MD; 14,080 deaths. The incidence of primary brain tumors Robert A. Fenstermaker, MD; Allan Friedman, MD; Mark R. Gilbert, MD; Deneen Hesser, MSHSA, RN, OCN; has been increasing over the past 30 years, especially in Matthias Holdhoff, MD, PhD; Larry Junck, MD; elderly persons.2 Metastatic disease to the CNS occurs Ronald Lawson, MD; Jay S. Loeffler, MD; Moshe H. Maor, MD; much more frequently, with an estimated incidence ap- Paul L. Moots, MD; Tara Morrison, MD; proximately 10 times that of primary brain tumors. An Maciej M. Mrugala, MD, PhD, MPH; Herbert B. Newton, MD; Jana Portnow, MD; Jeffrey J. Raizer, MD; Lawrence Recht, MD; estimated 20% to 40% of patients with systemic cancer Dennis C. Shrieve, MD, PhD; Allen K. Sills Jr, MD; will develop brain metastases.3 Abstract Please Note Primary and metastatic tumors of the central nervous system are The NCCN Clinical Practice Guidelines in Oncology a heterogeneous group of neoplasms with varied outcomes and (NCCN Guidelines®) are a statement of consensus of the management strategies.
    [Show full text]
  • Malignant Glioma Arising at the Site of an Excised Cerebellar Hemangioblastoma After Irradiation in a Von Hippel-Lindau Disease Patient
    DOI 10.3349/ymj.2009.50.4.576 Case Report pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 50(4): 576-581, 2009 Malignant Glioma Arising at the Site of an Excised Cerebellar Hemangioblastoma after Irradiation in a von Hippel-Lindau Disease Patient Na-Hye Myong1 and Bong-Jin Park2 1Department of Pathology, Dankook University College of Medicine, Cheonan; 2Department of Neurosurgery, Kyunghee University Hospital, Seoul, Korea. We describe herein a malignant glioma arising at the site of the resected hemangioblastoma after irradiation in a patient with von Hippel-Lindau disease (VHL). The patient was a 25 year-old male with multiple heman- gioblastomas at the cerebellum and spinal cord, multiple pancreatic cysts and a renal cell carcinoma; he was diagnosed as having VHL disease. The largest hemangioblastoma at the right cerebellar hemisphere was completely removed, and he received high-dose irradiation postoperatively. The tumor recurred at the same site 7 years later, which was a malignant glioma with no evidence of hemangioblastoma. The malignant glioma showed molecular genetic profiles of radiation-induced tumors because of its diffuse p53 immunostaining and the loss of p16 immunoreactivity. The genetic study to find the loss of heterozygosity (LOH) of VHL gene revealed that only the cerebellar hemangioblastoma showed allelic losses for the gene. To the best of our knowledge, this report is the first to show a malignant glioma that developed in a patient with VHL disease after radiation therapy at the site of an excised hemangioblastoma. This report also suggests that radiation therapy should be performed very carefully in VHL patients with hemangioblastomas.
    [Show full text]
  • Information About Mosaic Neurofibromatosis Type 2 (NF2)
    Information about mosaic Neurofibromatosis type 2 (NF2) NF2 occurs because of a mutation (change) in the NF2 gene. When this change is present at the time of conception the changed gene will be present in all the cells of the baby. When this mutation occurs later in the development of the forming embryo, the baby will go on to have a mix of cells: some with the “normal” genetic information and some with the changed information. This mix of cells is called mosaicism. Approximately half the people who have a diagnosis of NF2 have inherited the misprinted NF2 gene change from their mother or father who will also have NF2. They will have that misprinted gene in all the cells of their body. When they have their children, there will be a 1 in 2 chance of passing on NF2 to each child they have. However about half of people with NF2 are the first person in the family to be affected. They have no family history and have not inherited the condition from a parent. When doctors studied this group of patients more closely they noticed certain characteristics. Significantly they observed that fewer children had inherited NF2 than expected some people in this group had relatively mild NF2 NF2 tumours in some patients tended to grow on one side of their body rather than both sides that when a blood sample was tested to identify the NF2 gene, the gene change could not be found in 30-40% of people This lead researchers to conclude that this group of people were most likely to be mosaic for NF2 i.e.
    [Show full text]
  • Simultaneous Neurofibroma and Schwannoma of the Sciatic Nerve
    Simultaneous Neurofibroma and Schwannoma of the Sciatic Nerve 1 4 1 1 2 3 1 S. A. Sintzoff, Jr.,I.5 W . 0. Bank, · P. A. Gevenois, C. Matos, J. Noterman, J. Flament-Durand, and J. Struyven Summary: The authors report a case of simultaneously occur­ MR imaging was performed on a 0.5-T system (Gyro­ ring neurofibroma and schwannoma of the sciatic nerve and scan T5, Philips Medical Systems, Eindhoven, The Neth­ discuss the complementary aspects of MR and OS. The Schwan­ erlands) using a wrap-around knee surface coil in order to norna was well-defined and showed distal enhancement on better define the relationships between the tumors and the sonographic evaluation, whereas the neurofibroma was ill-de­ nerve. Each tumor was isointense to the normal nerve on fined; both tumors were hypoechoic. Tl- and T2-weighted MR T1-weighted images and hyperintense to it on proton Images revealed similar signal characteristics of the two tumors, density and T2-weighted images (Fig. 2A-2C). After intra­ but Intense enhancement following administration of gadolin­ venous gadolinium-DTPA injection, the distal mass showed ium-DTPA distinguished the schwannoma from the neurofi­ intense enhancement, conserving a thin hypointense border broma. (Fig. 2D). Physical and neurologic examination, MR of the central nervous system and skeletal radiographs failed to Index terms: Nerves, sciatic; Neuroma; Schwannoma demonstrate any additional lesions, permitting the reason­ able exclusion of neurofibromatosis types 1 and 2. Schwannomas and neurofibromas are com­ Surgical exposure demonstrated the two tumors on the external popliteal nerve (Fig. 3). The distal tumor could be (1, mon peripheral nerve neoplasms 2).
    [Show full text]
  • Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart
    Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor
    [Show full text]
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • A Rare Disease in Pediatric Patients
    Cartas ao Editor Jornal de Pediatria - Vol. 85, Nº 3, 2009 277 Resposta do autor Gliomatose leptomeníngea primária difusa: uma doença rara em pacientes pediátricos Prezado Editor, Recebemos com prazer os comentários acima. Os autores esclarecem que, em momento algum, focaram suas preo- Prezado Editor, cupações em critérios para definir síndrome metabólica, até mesmo porque se ela existe1, não existem critérios de consenso O recente relato de caso de Val Filho & Avelar1 sobre um para o diagnóstico em adultos2,3 tampouco em adolescentes. raro tumor cerebral pediátrico é interessante e merece grande Preocupamo-nos sim, em mostrar a presença de fatores de consideração no contexto da literatura publicada sobre esse risco em uma amostra selecionada ao acaso, que eles existem assunto, já que representa um evento muito incomum. Em em proporções tais que podem até ser agrupados, e, por um nome da precisão científica, devemos, portanto, fazer uma dos muitos critérios sugeridos na literatura, com valores de importante correção no que se refere ao diagnóstico. referências pediátricos, dar origem ao que se denomina sín- Os autores fizeram uma revisão breve e adequada sobre a drome metabólica. Não nos propusemos, portanto, a estudar gliomatose cerebral; uma doença rara, classificada pela edição associações entre fatores de risco. de 2007 da Organização Mundial da Saúde (OMS)2 como uma Os autores acreditam que discutir critérios para o que não lesão de grau III com prognóstico reservado. A gliomatose 2,3 existe consenso é desfocar a atenção da gravidade
    [Show full text]
  • 6 Magnetic Resonance Imaging
    Chapter 6 / MRI 105 6 Magnetic Resonance Imaging Paul M. Ruggieri Summary Magnetic resonance (MR) is clearly the accepted imaging standard for the preliminary evalua- tion, peri-operative management, and routine longitudinal follow-up of patients with high-grade glio- mas (HGG). The purpose of this chapter is to review the imaging characteristics of HGG using conventional MR imaging techniques. Whereas the newer techniques of MR diffusion, perfusion, diffusion tensor imaging, and MR spectroscopy will be included as part of this discussion of the high grade neoplasms, the detailed concepts of such studies will be discussed elsewhere in this text. Key Words: MR imaging; anaplastic astrocytoma; glioblastoma multiforme; gliosarcoma; gliomatosis cerebri; oligodendroglioma. INTRODUCTION Magnetic resonance (MR) is clearly the accepted imaging standard for the preliminary evaluation, peri-operative management, and routine longitudinal follow-up of patients with high-grade gliomas (HGG). The purpose of this chapter is to review the imaging characteristics of HGG using conventional MR imaging techniques. Whereas the newer techniques of MR diffusion, perfusion, diffusion tensor imaging, and MR spectroscopy will be included as part of this discussion of the high grade neoplasms, the detailed concepts of such studies will be discussed elsewhere in this text. In general terms, high-grade glial neoplasms are conventionally thought of as infiltrative parenchymal masses that are hyperintense on FLAIR fluid-attenuated inversion recovery (FLAIR) and T2-weighted images, hypointense on unenhanced T1-weighted images, may or may not extend into the corpus callosum, are surrounded by extensive vasogenic edema, and prominently enhance following gadolinium administration. It must be pointed out that this description is clearly just a generalization as many high-grade neoplasms clearly do not follow these “rules” and some of these characteristics may even be seen in low-grade neoplasms.
    [Show full text]
  • UCSD Moores Cancer Center Neuro-Oncology Program
    UCSD Moores Cancer Center Neuro-Oncology Program Recent Progress in Brain Tumors 6DQWRVK.HVDUL0'3K' 'LUHFWRU1HXUR2QFRORJ\ 3URIHVVRURI1HXURVFLHQFHV 0RRUHV&DQFHU&HQWHU 8QLYHUVLW\RI&DOLIRUQLD6DQ'LHJR “Brain Cancer for Life” Juvenile Pilocytic Astrocytoma Metastatic Brain Cancer Glioblastoma Multiforme Glioblastoma Multiforme Desmoplastic Infantile Ganglioglioma Desmoplastic Variant Astrocytoma Medulloblastoma Atypical Teratoid Rhabdoid Tumor Diffuse Intrinsic Pontine Glioma -Mutational analysis, microarray expression, epigenetic phenomenology -Age-specific biology of brain cancer -Is there an overlap? ? Neuroimmunology ? Stem cell hypothesis Courtesy of Dr. John Crawford Late Effects Long term effect of chemotherapy and radiation on neurocognition Risks of secondary malignancy secondary to chemotherapy and/or radiation Neurovascular long term effects: stroke, moya moya Courtesy of Dr. John Crawford Importance Increase in aging population with increased incidence of cancer Patients with cancer living longer and developing neurologic disorders due to nervous system relapse or toxicity from treatments Overview Introduction Clinical Presentation Primary Brain Tumors Metastatic Brain Tumors Leptomeningeal Metastases Primary CNS Lymphoma Paraneoplastic Syndromes Classification of Brain Tumors Tumors of Neuroepithelial Tissue Glial tumors (astrocytic, oligodendroglial, mixed) Neuronal and mixed neuronal-glial tumors Neuroblastic tumors Pineal parenchymal tumors Embryonal tumors Tumors of Peripheral Nerves Shwannoma Neurofibroma
    [Show full text]
  • Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma Or Ependymoma (Sjyc07)
    SJCRH SJYC07 CTG# - NCT00602667 Initial version, dated: 7/25/2007, Resubmitted to CPSRMC 9/24/2007 and 10/6/2007 (IRB Approved: 11/09/2007) Activation Date: 11/27/2007 Amendment 1.0 dated January 23, 2008, submitted to CPSRMC: January 23, 2008, IRB Approval: March 10, 2008 Amendment 2.0 dated April 16, 2008, submitted to CPSRMC: April 16, 2008, (IRB Approval: May 13, 2008) Revision 2.1 dated April 29, 2009 (IRB Approved: April 30, 2009 ) Amendment 3.0 dated June 22, 2009, submitted to CPSRMC: June 22, 2009 (IRB Approved: July 14, 2009) Activated: August 11, 2009 Amendment 4.0 dated March 01, 2010 (IRB Approved: April 20, 2010) Activated: May 3, 2010 Amendment 5.0 dated July 19, 2010 (IRB Approved: Sept 17, 2010) Activated: September 24, 2010 Amendment 6.0 dated August 27, 2012 (IRB approved: September 24, 2012) Activated: October 18, 2012 Amendment 7.0 dated February 22, 2013 (IRB approved: March 13, 2013) Activated: April 4, 2013 Amendment 8.0 dated March 20, 2014. Resubmitted to IRB May 20, 2014 (IRB approved: May 22, 2014) Activated: May 30, 2014 Amendment 9.0 dated August 26, 2014. (IRB approved: October 14, 2014) Activated: November 4, 2014 Un-numbered revision dated March 22, 2018. (IRB approved: March 27, 2018) Un-numbered revision dated October 22, 2018 (IRB approved: 10-24-2018) RISK-ADAPTED THERAPY FOR YOUNG CHILDREN WITH EMBRYONAL BRAIN TUMORS, HIGH-GRADE GLIOMA, CHOROID PLEXUS CARCINOMA OR EPENDYMOMA (SJYC07) Principal Investigator Amar Gajjar, M.D. Division of Neuro-Oncology Department of Oncology Section Coordinators David Ellison, M.D., Ph.D.
    [Show full text]
  • A Case of Cerebral Astroblastoma with Rhabdoid Features : a Cytological, Histological, and Immunohistochemical Study
    Title A case of cerebral astroblastoma with rhabdoid features : a cytological, histological, and immunohistochemical study Yuzawa, Sayaka; Nishihara, Hiroshi; Tanino, Mishie; Kimura, Taichi; Moriya, Jun; Kamoshima, Yuuta; Nagashima, Author(s) Kazuo; Tanaka, Shinya Brain tumor pathology, 33(1), 63-70 Citation https://doi.org/10.1007/s10014-015-0241-5 Issue Date 2016-01 Doc URL http://hdl.handle.net/2115/63975 Rights The final publication is available at link.springer.com Type article (author version) File Information Astroblastoma_yuzawa_HUSCAP.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Case report A case of cerebral astroblastoma with rhabdoid features: a cytological, histological, and immunohistochemical study Sayaka Yuzawa1, Hiroshi Nishihara2, 3, Mishie Tanino1, Taichi Kimura2, 3, Jun Moriya1, Yuuta Kamoshima4, 5, Kazuo Nagashima6, and Shinya Tanaka1, 2. 1Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan. 2Department of Translational Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 3Translational Research Laboratory, Hokkaido University Hospital, Clinical Research and Medical Innovation Center, Sapporo, Japan. 4Sapporo Azabu Neurosurgical Hospital, Sapporo, Japan. 5Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 6Higashi Tokushukai Hospital, Sapporo, Japan. Correspondence: Shinya Tanaka Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan. Tel: +81-11-706-5053 Fax: +81-11-706-5902 E-mail: [email protected] 1 Abstract Astroblastoma is a rare neuroepithelial neoplasm of unknown origin, usually occurring in children and young adults. Here we report a case of astroblastoma with uncommon features in an 18-year-old female.
    [Show full text]